Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Rhea-AI Summary
Alterity Therapeutics (NASDAQ: ATHE, ASX: ATH) reported its Q4 FY26 Appendix 4C and corporate update, highlighting FDA End-of-Phase 2 meeting minutes that confirm a registrational pathway for ATH434 in Multiple System Atrophy. According to Alterity, the FDA indicated that a single pivotal Phase 3 trial plus confirmatory evidence, expected from the Phase 2 ATH434-201 study, could support an NDA.
The planned Phase 3 trial is expected to enroll ~200 MSA patients, randomized 1:1 to ATH434 50 mg or placebo twice daily for 12 months, with an open-label extension. The company strengthened scientific positioning through multiple presentations and a NeuroImage publication validating QSM MRI iron mapping as an MSA biomarker.
Alterity reported a cash balance of A$37.3 million as of 30 June 2026, quarterly operating cash outflows of A$7.72 million, and receipt of an A$3.98 million Australian R&D Tax Incentive refund after quarter end. The company completed a 1-for-50 share consolidation and appointed Ann Cunningham as an independent non-executive director while continuing to evaluate strategic funding and partnering options for Phase 3.
Positive
- FDA-aligned registrational path – single pivotal Phase 3 plus confirmatory evidence for ATH434 in MSA
- Phase 3 trial design defined – ~200 patients, 12-month dosing, agreed primary and secondary endpoints
- Strong cash position – A$37.3 million at 30 June 2026
- R&D tax refund – A$3.98 million received after quarter end
- Share consolidation completed – 1-for-50 basis following shareholder approval
- Board strengthened – appointment of independent non-executive director Ann Cunningham
Negative
- High cash burn – operating cash outflows of A$7.72 million in Q4 FY26
News Explained
Alterity reports that Phase 3 preparation has reached manufacture of the first registration batch of ATH434, while trial activities remain planned for initiation by year-end
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | Investor conference participation | Neutral | +5.1% | CEO scheduled investor meetings at the virtual BTIG Biotechnology Conference |
| Jul 07 | FDA pathway confirmation | Positive | -6.8% | FDA confirmed a single pivotal Phase 3 trial could support potential approval |
| Jun 09 | FDA Phase 3 alignment | Positive | +9.4% | FDA aligned with the pivotal Phase 3 program design for ATH434 |
| May 19 | Phase 2 clinical data | Positive | -1.5% | Phase 2 analyses supported advancement of ATH434 into Phase 3 |
| May 11 | MRI biomarker publication | Positive | +3.0% | Peer-reviewed publication reported QSM utility as an MSA biomarker |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive development announcements produced mixed price reactions, including both gains and declines.
Key Terms
end-of-phase 2 regulatory
new drug application regulatory
quantitative susceptibility mapping medical
chemistry, manufacturing and control regulatory
umsars part i medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Highlights
- FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)
- FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA
- Pivotal Phase 3 trial activities on track to initiate by year-end 2026
- Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value
- Peer-reviewed publication in NeuroImage validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA
- Strengthened the Board of Directors with the appointment of Ms Ann Cunningham
- A
$3.98 million Australian R&D Tax Incentive refund received subsequent to quarter end, supporting continued development of Alterity’s clinical programs - Cash balance of A
$37.3 million as at 30 June 2026
MELBOURNE, Australia and SAN FRANCISCO, July 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2026 (Q4 FY26).
“This was a defining quarter for Alterity, highlighted by our positive End of Phase 2 meeting with the FDA that established a clear, efficient registrational pathway for ATH434,” said David Stamler, M.D., Chief Executive Officer. “With the Phase 3 design elements agreed upon, we are executing on our plans to initiate Phase 3 trial activities by year-end 2026.”
Dr. Stamler continued, “The regulatory clarity we have now achieved, together with the growing body of clinical evidence supporting ATH434, puts us in a strong position as we prepare to initiate Phase 3 and continue strategic and other funding discussions aimed at maximising the long-term value of the program.”
ATH434 Clinical and Regulatory Update
Alterity achieved several key regulatory milestones during the quarter. The Company reached alignment with the U.S. Food and Drug Administration (FDA) at its End-of-Phase 2 (EOP2) meeting on the registrational pathway for a potential New Drug Application (NDA) for ATH434 in MSA. At the meeting, the FDA indicated that a single pivotal trial plus confirmatory evidence could provide the data necessary to support approval, with the Company anticipating that the data from its ATH434-201 Phase 2 clinical trial will provide the required confirmatory evidence. This outcome represents one of the most significant regulatory milestones achieved by the Company to date and de-risks the regulatory pathway toward potential approval of ATH434 in MSA. Successful completion of the planned Phase 3 program has the potential to support the first disease-modifying treatment approved for Multiple System Atrophy, a rare and rapidly progressive neurodegenerative disease with no approved therapy.
Alignment was reached with the agency on several key elements of the proposed Phase 3 trial design, including the study population, treatment regimen and the use of the 11-item UMSARS Part I rating scale1 as the primary endpoint. Key secondary endpoints that assess key areas of impairment in MSA were agreed upon and the FDA also indicated that the anticipated size of the safety database at the conclusion of the Phase 3 trial was reasonable. The study is expected to enroll approximately 200 patients who will be randomized 1:1 to ATH434 50 mg or matching placebo treatment twice daily for 12 months. Alterity plans to offer an open-label extension to participants who complete the Phase 3 trial, both to continue their treatment and to enhance the safety database for ATH434.
In April 2026, Alterity announced positive FDA feedback following a Type C meeting related to the chemistry, manufacturing and control (CMC) elements of the Phase 3 program. In preparation for Phase 3, Alterity has successfully manufactured the first registration batch of ATH434 for use in the pivotal trial.
Scientific Engagement
Alterity continues to actively engage with the global neurology community through multiple scientific presentations at leading international congresses. These presentations formed an important component of the Company’s strategy to disseminate clinical data, engage with key opinion leaders and specialists, and further interpret Phase 2 results for ATH434 in MSA.
During the quarter, Alterity delivered the following presentations, which are available on the Publications and Presentations page of the Company’s website:
- April 2026 – American Academy of Neurology (AAN) Annual Meeting, Late-Breaking Science: An analysis using the newly described MSA Combined Outcome Assessment (MuSyCA)2 composite scale, which integrates items from UMSARS Parts I and II, showed ATH434 slowed functional decline versus placebo at Week 52, consistent with previously reported activity on the 11-item UMSARS Part I.
- May 2026 – Peer-reviewed publication in NeuroImage: A study drawing on the Company’s bioMUSE Natural History Study demonstrated that quantitative susceptibility mapping (QSM) of brain iron detects disease-specific accumulation in MSA, distinguishes MSA from Parkinson’s disease, and correlates with clinical severity in MSA.
- May 2026 – Three international scientific presentations at the International Society for Magnetic Resonance in Medicine (ISMRM), the Movement Disorder Society of Australia and New Zealand (MDSANZ) Scientific Meeting, and the MSA Symposium (University College London), presenting QSM imaging, CSF NfL3 covariate analyses and swallowing outcome data supporting ATH434’s mechanism as an iron chaperone.
Also during the period, the Company hosted a virtual key opinion leader (KOL) event featuring Roy Freeman, M.D. (Harvard Medical School) and Daniel Claassen, M.D., M.S. (Vanderbilt University Medical Center), alongside CEO David Stamler, M.D., to discuss the unmet need and treatment landscape in MSA and the ATH434 development program.
Strategic Partnering and Funding Alternatives
Alterity continues to evaluate a range of strategic and funding alternatives to support the advancement of ATH434, including ongoing discussions with a number of pharmaceutical companies. The Company is progressing a structured evaluation process, with the assistance of external advisers, to assess these opportunities alongside other potential funding and development pathways.
The Company remains focused on maintaining strategic flexibility while pursuing the pathway that best supports the advancement of ATH434 and maximises long-term shareholder value.
Corporate and Financial Update
Governance and Leadership
In April 2026, the company announced the appointment of Ms Ann Cunningham to the Board of Directors as an independent Non-Executive Director. Ms Cunningham’s appointment adds global commercial and strategic expertise as the company transitions toward late-stage development in MSA.
Share Consolidation
Following shareholder approval at the Extraordinary General Meeting held on 29 May 2026, the Company completed a consolidation of its share capital on a 1-for-50 basis.
Cash Position
As of 30 June 2026, Alterity held cash and cash equivalents of A
Subsequent to quarter-end, on 9 July 2026, the Company received its research and development (R&D) tax refund for the 2025 financial year totaling A
In accordance with ASX Listing Rule 4.7C, payments of A
The full financial report can be found in the ASX filing here.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.
References
1 11-item UMSARS Part I (previously described as modified UMSARS I): Unified Multiple System Atrophy Rating Scale, 11-Items include: Orthostatic symptoms, Swallowing, Speech, Handwriting, Cutting food, Dressing, Hygiene, Walking, Falling, Urinary and Bowel function.
2 For the MuSyCa MSA Combined Outcome assessment: UMSARS I items were swallowing, handwriting, utensils, dressing, hygiene, walking; UMSARS I items were speech, leg agility, arising from chair, body sway, gait
3 Neurofilament Light Chain measured in the cerebrospinal fluid (CSF)
Authorisation & Additional information
This announcement was authorized by the Board of Directors of Alterity Therapeutics Limited.
Contacts:
Investors
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Melissa Tempra
NWR Communications
melissa@nwrcommunications.com.au
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
